toxylact: a07ba01 medicinal chargoal

The first professional lActological database in the word

Medicinal charcoal (ATC A07BA01) is an activated‑charcoal intestinal adsorbent used mainly for common diarrhea and digestive complaints, with negligible systemic absorption and a very low theoretical risk during breastfeeding.atcddd.fhi+3

ATC A07BA01 definition

ATC code A07BA01 designates “medicinal charcoal,” the prototypical activated‑charcoal preparation within the subgroup A07BA Charcoal preparations. It is classified among intestinal adsorbents for antidiarrheal therapy, with a defined daily dose of 5 g orally, based on treatment of common diarrhea.atcddd.fhi+1

Pharmaceutical forms and typical uses

Medicinal charcoal A07BA01 is marketed as hard capsules and tablets containing various strengths of activated charcoal (for example, 150–300 mg per unit), often as single‑ingredient products. These formulations are intended for oral use as over‑the‑counter or prescribed agents to relieve diarrhea, bloating, and other minor gastrointestinal complaints, and in some contexts as supportive therapy in dyspepsia.atcddd.fhi+4

Mechanism of action

Activated charcoal is a highly porous, carbon‑based material with a large internal surface area that adsorbs drugs, bacterial toxins, gases, and other xenobiotics within the gastrointestinal lumen. By binding these substances, medicinal charcoal reduces their bioavailability, dampens local mucosal irritation, and can help normalize stool consistency and gas production.drugbank+3

Therapeutic indications

Within the A07BA01 designation, medicinal charcoal is used primarily as a symptomatic treatment for common, usually self‑limited diarrhea, with dosing aligned to the 5 g DDD for this indication. Many medicinal‑charcoal products are also labeled to “support the digestive system and intestines,” including reduction of excessive flatulence and support of lipid metabolism, although such uses are often regulated as dietary supplements rather than strictly medicinal indications.atcddd.fhi+2

Pharmacokinetics and systemic exposure

Activated charcoal is considered biologically inert and is not absorbed from the intact gastrointestinal tract; it remains confined to the lumen and is excreted unchanged in the feces. As a result, systemic exposure to charcoal itself is effectively zero at therapeutic doses of A07BA01, which is central to its favorable safety profile in both general and lactating populations.wikipedia+2

Maternal safety profile

Common adverse effects of medicinal charcoal include black stools, constipation or, less often, diarrhea, reflecting its local action in the intestine. At higher total doses (for example when products are used off‑label in poisoning), more serious but uncommon risks include gastrointestinal obstruction and, if aspirated, pneumonitis, so use is contraindicated in suspected intestinal obstruction or in patients unable to safely swallow.ncbi.nlm.nih+1

Lactation safety assessment

General lactation‑pharmacology principles emphasize that non‑absorbed oral agents have extremely low potential to reach breast milk and are typically categorized as compatible with breastfeeding. Because medicinal charcoal is not absorbed, clinically relevant transfer into human milk is not expected, and its use at A07BA01 doses for diarrhea is considered very low risk for the breastfed infant.ncbi.nlm.nih+6

Potential effects on the breastfed infant

Direct exposure of the infant to medicinal charcoal via breast milk is expected to be negligible, so charcoal‑related toxicity or interference with infant nutrient absorption is not anticipated. Any risk to the infant is more likely related to the underlying maternal condition (for example infectious diarrhea) or to co‑administered systemic medicines, which should be evaluated separately for milk transfer and infant effects.research.rug+4

Practical recommendations in breastfeeding

For breastfeeding women using medicinal charcoal at standard A07BA01 doses for mild, self‑limited diarrhea or bloating, breastfeeding can usually continue without dose‑timing adjustments, alongside oral rehydration and appropriate dietary measures. Clinicians should verify that the product does not contain additional active substances of concern (such as certain herbs or laxatives) and should avoid prolonged, unnecessary use, documenting benefit, duration, and any infant monitoring in the medical record.pure.eur+5

Risk–benefit balance

In the context of symptomatic gastrointestinal treatment during lactation, medicinal charcoal A07BA01 offers local efficacy, negligible systemic and milk exposure, and a favorable adverse‑effect profile, leading to a clearly positive risk–benefit balance when used appropriately. The main safeguards are correct indication (short‑term, mild gastrointestinal symptoms), attention to contraindications, and a separate assessment of any systemic drugs or diseases that may impact breastfeeding safety.pure.eur+6

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.